Healgen Scientific Exhibits Broad Diagnostic Portfolio at ADLM 2026
Posted on 29 Jul 2026
At ADLM 2026, Healgen Scientific is showcasing a broad diagnostic portfolio covering infectious diseases, toxicology, women’s health, urinalysis, fluorescent immunoassays, point-of-care testing, biochemistry, and animal health. The company is presenting these solutions during the Clinical Lab Expo, held July 26–30 at the Anaheim Convention Center in California.
A key focus of the company’s exhibit is infectious disease testing. Healgen is showcasing rapid tests for respiratory infections, sexually transmitted infections, blood-borne diseases, and tropical and vector-borne conditions, including malaria, dengue, and Zika. The portfolio is designed to support testing across laboratories, clinics, and point-of-care environments.
In toxicology, Healgen is presenting urine and oral-fluid drug tests alongside harm-reduction products. The company is also highlighting the HealSnap mobile application, which supports its toxicology testing solutions and is intended to extend digital capabilities around rapid test workflows.
The company’s women’s health portfolio includes tests for pregnancy, ovulation, menopause, urinary tract infections, and vaginal pH. Healgen is additionally featuring multiparameter urinalysis strips covering clinical chemistry indicators such as glucose, ketones, protein, nitrite, and microalbumin.
Healgen is also showcasing benchtop and handheld fluorescent immunoassay platforms designed for testing across multiple clinical areas. Available applications include anemia, cardiovascular disease, diabetes, fertility, kidney injury, respiratory disease, thyroid disorders, and toxicology.
For laboratories seeking instrument-based and automated workflows, the exhibit includes the GeneStream real-time PCR system, the CLIA-go Pro platform, chemiluminescence technologies, automatic biochemistry analyzers, and dry chemistry systems. These solutions are intended to address testing needs ranging from decentralized clinical settings to professional and high-throughput laboratories.
The company is additionally presenting animal health solutions for companion and food animals. The portfolio includes rapid tests, molecular diagnostic technologies, and biochemistry systems designed to support veterinary testing across different care and production environments.
Through its ADLM 2026 exhibit, Healgen is highlighting the breadth and scalability of its diagnostic portfolio across human and veterinary health. The showcase demonstrates how the company’s rapid tests, analyzers, and point-of-care systems can support diverse sample types, testing volumes, and clinical applications.
